Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        For Patients

Rare Diseases at FDA Home
          For Patients
          Rare Diseases at FDAFor Patients Rare Diseases at FDA
  	
        Share
    Post
    Linkedin

    Email
    PrintOver 7,000 rare diseases affect more than 30 million people in the United States. Many rare conditions are life-threatening and most do not have treatments. Drug, biologic, and device development in rare diseases is challenging for many reasons, including the complex biology and the lack of understanding of the natural history of many rare diseases. The inherently small population of patients with a rare disease can also make conducting clinical trials difficult. Since the Orphan Drug Act was signed into law in 1983, the FDA has approved hundreds of drugs for rare diseases, but most rare diseases do not have FDA-approved treatments.  The FDA works with many people and groups, such as patients, caregivers, and drug and device manufactures, to support rare disease product development.

On this page: What is a rare disease? | What is the Orphan Drug Act? | What is an orphan drug? | How does the FDA encourage product development for rare diseases? | What does the FDA Office of Orphan Products Development do? | How do the FDA medical product centers support rare disease product development? | How can patients become involved in FDA’s work on rare diseases?


**What is a rare disease?**

The Orphan Drug Act defines a rare disease as a disease or condition that affects less than 200,000 people in the United States.

Back to top

**What is the Orphan Drug Act?**

The Orphan Drug Act is a law passed by Congress in 1983 that incentivizes the development of drugs to treat rare diseases. 
Companies and other drug developers can request orphan drug designation and FDA will grant such designation if the drug meets specific criteria.  Orphan designation qualifies sponsors for various incentives, including:

Tax credits for qualified clinical (in humans) testing
	Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug)
	Potential 7 years of market exclusivity after approvalIn addition, the Orphan Drug Act established the Orphan Product Grants Program to provide funding for developing products for rare diseases or conditions.

Back to top

**What is an orphan drug?**

An orphan drug is a drug for a rare disease or condition. Some rare disease treatments have been “orphaned” or discontinued because there was not enough financial incentive to continue development or production. The Orphan Drug Act incentivizes drug development for rare diseases.

Back to top

**How does the FDA encourage the development of medical products to diagnose and treat rare diseases?**

The FDA works with stakeholders, including patients, patient advocates, product developers, and researchers, to support the development of safe and effective drugs, biologics, and devices  for rare diseases.

The FDA is one part of the many parts involved in finding and developing treatments for rare diseases. Specifically, the FDA:

Administers Laws and Regulations

Carries out the Orphan Drug Act and related laws and regulationsReviews and Grants Designations to Rare Disease Drugs, Rare Pediatric Diseases, and Devices

Evaluates whether a drug or device qualifies for designation, based on whether both the product and the disease must meet certain criteria specified in the relevant laws. Relevant designation programs for rare diseases include the orphan drug, rare pediatric disease, and humanitarian use device designation programs.  Also, FDA reviews and awards Rare Pediatric Disease Priority Review Vouchers.Regulates Drugs and Devices

Protects the public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devicesGives Research Grants

Awards grants for research on rare diseases, including grants for clinical trials, natural history studies, and pediatric device consortiumConducts Outreach

Communicates with professional organizations, patients, and rare disease advocacy groups about rare disease issuesBack to top

**What does the FDA Office of Orphan Products Development do?**

The FDA’s Office of Orphan Products Development:

Coordinates FDA activities for rare diseases
	Administers the orphan drug, rare pediatric disease, and humanitarian use device designation programs
	Funds grants and cooperative agreements for rare disease research
	Is a central point-of-contact for patients, caregivers, and advocacy groups who have questions about the FDA’s work in rare diseasesLearn more about the FDA Office of Orphan Products Development.

Back to top

**How do the FDA medical product centers support rare disease product development?**

The FDA Center for Drug Research and Evaluation (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Device and Radiological Health (CDRH) all support the development and approval of safe and effective drugs, biologics, and devices to treat rare diseases.

To address specific considerations in developing and approving medical products for rare diseases, the FDA centers:

Conduct specialized training for FDA staff on rare disease topics
	Issue guidances for industry to encourage medical product development in rare diseases
	Host and participate in patient-focused meetings and listening sessions on rare disease topics
	Award research grants, cooperative agreements, and contracts in addition to conducting pilot programs and special data analyses to advance the regulatory science for rare diseases
	Administer the expanded access or compassionate use program for investigational medical products in their specific area
	Participate in FDA’s Rare Disease Council to discuss rare disease issues
	Collaborate on FDA’s annual Rare Disease Day eventRead more about CDER’s Rare Diseases Program and Accelerating Rare disease Cures (ARC) Program

Read more about CBER’s Rare Disease Program.

Read more about CDRH’s Breakthrough Devices Program and the Humanitarian Use Device and Humanitarian Device Exemption programs.

Back to top

**How can patients become involved in FDA’s work on rare diseases?**

The FDA’s Patient Affairs Staff partners with the National Organization for Rare Disorders (NORD) to host Patient Listening Sessions that focus on rare diseases. Patient Listening Sessions are one of many ways the patient community can share their experience with a disease or condition by talking directly with FDA staff.

We encourage rare disease patients and caregivers to contactour Patient Affairs Staff with any questions they might have about the FDA, treatments for their disease, and how they can participate in FDA processes. Patients or caregivers may also request a meeting by using the Patient Portal at www.fda.gov/PatientsAskFDA.

Learn more about the FDA’s Patient Engagement work.

Back to top

                                                                                  Content current as of:
      12/13/2022
                  
                   
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical DevicesRare Diseases at FDA
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop